IL6 and rheumatoid arthritis: The targets of these drugs are very wide; tocilizumab (TCZ) acts through the inhibition of IL-6, another proinflammatory cytokine that may contribute to atherosclerosis processes; in fact, TCZ improves endothelial function and aortic stiffness in RA and this despite the increase of total and LDL-cholesterol [58].